Table 2.

Scenario Analyses With the Assumption of No Difference in Mortality

	Costs	Incremental Costs	Effectiveness	Incremental Effectiveness	ICER
Korean health care system perspective
Aspirin	14,462	–	12.363	–	–
Clopidogrel	17,656	3,194	12.405	0.042	75,428
UK health care system perspective
Aspirin	7,333	1,050	13.396	–0.105	Dominated
Clopidogrel	6,283	–	13.500	–	Dominant
U.S. health care system perspective
Aspirin	112,479	8,071	15.167	–0.066	Dominated
Clopidogrel	104,408	–	15.233	–	Dominant

For the analyses from the South Korean and U.S. health care system perspectives, the unit of costs was U.S. dollars. For the analysis from the UK health care system perspective, the unit of the cost was the British pound. For all analyses, the unit of effectiveness was quality-adjusted life-years.

Abbreviations as in Table 1.